Galena completes patient enrolment in Phase II GALE-401 trial

Galena Biopharma has completed patient enrolment in the GALE-401, or Anagrelide Controlled Release, Phase II clinical trial to treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news